Oculis
$4.22
20
+$0.00+0% Friday 19:38
Statistics
Day High
4.22
Day Low
4.22
52W High
4.22
52W Low
4.22
Volume
1,600
Avg. Volume
-
Mkt Cap
235.79M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
6AugExpected
Expected EPS
-0.484721487
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-191MNet Income
Analyst Ratings
35.00Average Price Target
The highest estimate is 45.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow OCSAW. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap63.95B
Novartis
NVS
Mkt Cap280.64B
Abbvie
ABBV
Mkt Cap382.49B
Regenxbio
RGNX
Mkt Cap459.07M
Bausch Health Companies
BHC
Mkt Cap1.78B
Rogers
ROG
Mkt Cap2.9B
GSK
GSK
Mkt Cap101.54B
Astrazeneca
AZN
Mkt Cap271.29B
About
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Show more...
CEO
Dr. Riad Sherif M.B.A., M.D.
Employees
49
Country
Switzerland
ISIN
CH1246223429
Listings
0 Comments
Share your thoughts
FAQ
What is Oculis stock price today?▼
The current price of OCSAW is $4.22 USD — it has increased by +0% in the past 24 hours. Watch Oculis stock price performance more closely on the chart.
What is Oculis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oculis stocks are traded under the ticker OCSAW.
Is Oculis stock price growing?▼
OCSAW stock has fallen by -13.88% compared to the previous week, the month change is a -77.79% fall, over the last year Oculis has showed a -52.32% decrease.
What is Oculis market cap?▼
Today Oculis has the market capitalization of 235.79M
When is the next Oculis earnings date?▼
Oculis is going to release the next earnings report on August 06, 2026.
What were Oculis earnings last quarter?▼
OCSAW earnings for the last quarter are -0.61 USD per share, whereas the estimation was -0.5 USD resulting in a -22.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oculis revenue for the last year?▼
Oculis revenue for the last year amounts to 0 USD.
What is Oculis net income for the last year?▼
OCSAW net income for the last year is -191M USD.
How many employees does Oculis have?▼
As of June 27, 2026, the company has 49 employees.
In which sector is Oculis located?▼
Oculis operates in the Health & Wellness sector.
When did Oculis complete a stock split?▼
Oculis has not had any recent stock splits.
Where is Oculis headquartered?▼
Oculis is headquartered in Zug, Switzerland.